Volume 52 | Number 6 | December 2017

Abstract List

Adam A. Markovitz B.S., Rob G. Holleman M.P.H., Timothy P. Hofer M.D., M.S., Eve A. Kerr M.D., M.P.H., Mandi L. Klamerus M.P.H., Jeremy B. Sussman M.D., M.S.


To compare the effects of two sequential policy changes—the addition of a high‐potency statin to the Department of Veterans Affairs () formulary and the release of the American College of Cardiology/American Heart Association (/) cholesterol guidelines—on provider prescribing.

Data Sources/Study Setting

Retrospective analysis of 1,100,682 patients, 2011–2016.

Study Design

Interrupted time‐series analysis of changes in prescribing of moderate‐to‐high‐intensity statins among high‐risk patients and across high‐risk subgroups. We also assessed changes in prescribing of atorvastatin and other statin drugs. We estimated marginal effects () of formulary and guideline changes by comparing predicted and observed statin use.

Data Collection/Extraction Methods

Data from Corporate Data Warehouse.

Principal Findings

The use of moderate‐to‐high‐intensity statins increased by 2 percentage points following the formulary change (, 2.4, 95% confidence interval [], 2.2 to 2.6) and less than 1 percentage point following the guideline change (, 0.8, 95% , 0.6 to 0.9). The formulary change led to approximately a 12 percentage‐point increase in the use of moderate‐to‐high‐intensity atorvastatin (, 11.5, 95% , 11.3 to 11.6). The relatively greater provider response to the formulary change occurred across all patient subgroups.


Addition of a high‐potency statin to formulary affected provider prescribing more than the / guidelines.